Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study

Leukemia

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group

Leuk Lymphoma

Soboń A, Iskierka-Jażdżewska E, Drozd-Sokolowska J, Puła A, Gajewska M, Danecki M, Bołkun Ł, Ogłoza-Puchowska A, Morawska M, Halka J, Subocz E, Podgórska A, Tryc-Szponder J, Paszkiewicz-Kozik E, Czernik L, Kopinska A, Rybka J, Szymczyk A, Wdowiak K, Steckiewicz P, Gołos A, Hus I, Jamroziak K, Robak T, Lech-Maranda E, Puła B

doi: 10.1080/10428194.2026.2690480

Leukemia

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Br J Haematol

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M

doi: 10.1111/bjh.70418

Non-Malignant Blood Disorders

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Br J Haematol

Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H

doi: 10.1111/bjh.70531

Leukemia

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Br J Haematol

Duminuco A, Leotta D, Allegra A, Caracciolo D, Caruso L, Chiarenza A, Del Fabro V, Di Martina V, Figuera A, Fiumara PF, Gentile M, Innao V, Mancuso S, Martino EA, Mosca A, Motta G, Pedalino F, Rossi M, Stagno F, Tona G, Di Raimondo F, Palumbo GA

doi: 10.1111/bjh.70638

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Myeloproliferative Neoplasms (MPNs)

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom

Br J Haematol

Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP, UK Blood Cancer Research Network MPN Clinical Study Group

doi: 10.1111/bjh.70511

Leukemia

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy

Leuk Lymphoma

Fradin JJ, Rein L, Szabo A, Carlson KS, Badar T, Holden T, Shah S, Im A, Patel AA, Atallah E

doi: 10.1080/10428194.2026.2684259

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Leukemia

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis

Haematologica

Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F

doi: 10.3324/haematol.2026.300764

Related content

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis